Ensayos clínicos

NRG-CC011 Cognitive Training for Breast Cancer Survivors
Sponsor: NRG
Study: NRG-CC011
Cancer Stage: Stage I-III

Description: Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial

Inclusions:

• First time diagnosis of non-metastatic breast cancer stage I-III

Exclusions:

• Participants with history of stroke, traumatic brain injury, brain surgery, Alzheimer’s disease or other dementia
• Active substance abuse and/or in treatment for substance abuse, or history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.

Prior treatment: 

• Allowed

Purpose: 

• The goal of this trial is to determine the efficacy of advanced cognitive training for cancer survivors suffering from cancer- and cancer-treatment-related cognitive dysfunction.

Basic Qualifications: 

• First time diagnosis of non-metastatic breast cancer

NRG-CC011 Brochure

NRG-GY028
Sponsor: NRG
Study: GY028
Cancer Stage: Recurrent or Metastatic Endometrioid Endometrial Cancer

Description: A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer.

Inclusions:

• Patients must have grade 1 or 2 recurrent or metastatic endometrioid endometrial cancer.
• Measurable disease
• ECOG 0-2

Exclusions:

• Listed in protocol

Prior treatment: 

• Allowed

Purpose: 

• To compare the progression free survival of the combination of ipatasertib with megestrol acetate to megestrol acetate alone among women with metastatic grade 1-2 endometrioid adenocarcinoma of the endometrium.

Basic Qualifications: 

• See inclusions

XPORT-EC-042
Sponsor: Karyopharm Therapeutics Inc.
Study: XPORT-EC-042
Cancer Stage: Advanced or Recurrent Endometrial Carcinoma

Description: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Inclusions:

• TP53 Wildtype
• Contact research staff

Exclusions:

• Any uterine sarcomas (carcinosarcomas – not excluded), clear cell or small cell carcinoma with neuroendocrine differentiation.

Prior treatment: 

• Allowed

Purpose: 

• To evaluate efficacy and safety for maintenance administration of Selinexor in patients with TP53 wildtype (no TP53 alterations) advanced or recurrent Endometrial Carcinoma

Basic Qualifications: 

• See inclusions

Amgen 20210023 for solid tumors
Sponsor: Amgen
Study: 20210023
Cancer Stage: Metastatic, locally advanced, or not amenable to curative treatment with surgery and/or radiation MTAP-null solid tumors

Description: A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel.

Inclusions:

• Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) (Parts 1a, 1j, 1k, and 2a only) and/or methylthioadenosine phosphorylase (MTAP) (null) in the tumor tissue or blood (Parts 1a to 1k, Parts 2a and 2b) or lost MTAP expression in the tumor tissue (Parts 1a to 1k, Parts 2a and 2b)
• Measurable disease
• ECOG 0-1

Exclusions:

• Untreated brain metastases
• Myocardial infarction and/or CHF
• Prior treatment with docetaxel (Part 2 only)
• Prior irradiation to 25% of the bone marrow

Prior treatment:

• Allowed

Purpose:

• To evaluate safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel

Basic Qualifications:

• See inclusions

NRG-BN013
Sponsor: NRG Oncology
Study: BN013
Cancer Stage: Metastatic

Description: A Phase III trial for brain metastases

Inclusions:

• Pathologically (histologically or cytologically) proven diagnosis of one of the following cancers
  • Non-small cell lung
  • Melanoma
  • Breast
  • Renal cell
  • Gastrointestinal
• Must have at least 1 and up to 8 total intact brain metastases on MRI and outside of the brainstem

Exclusions:

• No prior radiotherapy to the brain

Prior treatment:

• No prior radiotherapy to the brain

Purpose:

• To determine if the time to local failure is improved with FSRS compared to SRS in patients with intact (i.e., unresected) brain metastases

Basic Qualifications:

• Same as inclusion criteria

GCP-PRT-101-001 for solid tumors with brain mets
Sponsor: Radiopharm Therano
Study: GCP-PRT-101-001
Cancer Stage: Suspected Recurrent Brain Metastases from Solid Tumors

Description: An Open-Label, Single Dose, Single Arm, Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission Tomography (PET) in Participants with Suspected Recurrent Brain Metastases from Solid Tumors.

Inclusions:

• One of the following histopathologically confirmed advanced solid tumors with known history of brain metastases: lung, breast, colon, kidney, or melanoma.
• Participant had SRS within up to 12 months prior to screening
• Suspected brain metastasis in at least 1 but not more than 5 previously treated brain mets

Exclusions:

• Brain surgery within 4 weeks before screening

Prior treatment: 

• Allowed

Purpose: 

• To establish the imaging performance of RAD101 PET in participants with suspected recurrent brain metastases from solid tumors.

Basic Qualifications: 

• See inclusions

Tempus ARIES Trial- Biobank Registry
Sponsor: Tempus AI, Inc.
Study: TP-CA-007
Cancer Stage: Various cohorts available

Description: A Biobank Registry Platform Study in Oncology. This Study is a multisite, multicohort, master biospecimen collection non-interventional Study using participant data and blood samples at prospectively defined time points for ctDNA analysis to answer cohort-based research questions. The Study will not affect participants’ clinical care or access to care.

Inclusions: 

• Contact research center

Exclusions:

Prior treatment:

Purpose: 

• Collection of blood samples before, during and after treatment to determine if the genetic makeup of the tumor has changed

Basic Qualifications: